Zevra Therapeutics to Report Second Quarter 2024 Financial Results
July 30, 2024 08:38 ET
|
Zevra Therapeutics
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a...
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
July 09, 2024 09:00 ET
|
Zevra Therapeutics
CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and...
Zevra Therapeutics Expands Executive Leadership Team
June 25, 2024 07:30 ET
|
Zevra Therapeutics
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra...
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
June 03, 2024 11:00 ET
|
Zevra Therapeutics
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on...
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
October 05, 2023 07:30 ET
|
Zevra Therapeutics
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs CELEBRATION, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Zevra...
ORPH FINAL DEADLINE ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
September 05, 2021 13:15 ET
|
The Rosen Law Firm PA
NEW YORK, Sept. 05, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
ORPH BREAKING ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ORPH
August 24, 2021 17:45 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers
June 24, 2020 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 36/2020 ...
Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis
May 22, 2020 01:52 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
January 03, 2020 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....